Literature DB >> 8727333

True epineural neurolysis in Morton's neuroma: a 5-year follow up.

P F Diebold, B Daum, V Dang-Vu, M Litchinko.   

Abstract

Morton's neuroma is a frequent cause of metatarsalgia. Neuroma resection was the usual recommended surgical treatment. Failure rate of neurectomy can be as high as 14% to 21%, and treatment of recurrences is difficult. The authors have treated Morton's neuroma by neurolysis since 1985. They present their results in a group of 40 patients with 5 years follow up. Thirty-seven of 40 patients had an excellent result after neurolysis and 35 patients had normal toe sensitivity at the date of examination. Thirty-nine patients stated they would undergo the operation again if necessary.

Entities:  

Mesh:

Year:  1996        PMID: 8727333     DOI: 10.3928/0147-7447-19960501-09

Source DB:  PubMed          Journal:  Orthopedics        ISSN: 0147-7447            Impact factor:   1.390


  4 in total

1.  The role of fasciae in Civinini-Morton's syndrome.

Authors:  Carla Stecco; Ilaria Fantoni; Veronica Macchi; Mario Del Borrello; Andrea Porzionato; Carlo Biz; Raffaele De Caro
Journal:  J Anat       Date:  2015-09-11       Impact factor: 2.610

2.  The outcome of Morton's neurectomy in the treatment of metatarsalgia.

Authors:  Alistair Pace; Brigitte Scammell; Sunil Dhar
Journal:  Int Orthop       Date:  2009-05-30       Impact factor: 3.075

3.  Treatment of intermetatarsal Morton's neuroma with alcohol injection under US guide: 10-month follow-up.

Authors:  Ezio Fanucci; Salvatore Masala; Sebastiano Fabiano; Dario Perugia; Ettore Squillaci; Viviana Varrucciu; Giovanni Simonetti
Journal:  Eur Radiol       Date:  2003-10-03       Impact factor: 5.315

4.  Long-term results of dorsal neuroma/nerve transposition in the surgical management of Morton's neuroma and correlation with intraoperative anatomical variations.

Authors:  Manjunath Koti; Nicola Maffulli; Muwaffak Al-Shoaibi; Michael Hughes; Jack McAllister
Journal:  J Orthop Surg Res       Date:  2022-01-15       Impact factor: 2.359

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.